Andrew Cheng
Independent DirectorDr. Andrew Cheng, MD, PhD, is Independent Director of TCGX Acquisition Corp. from August 4, 2026. Dr. Cheng serves as Director at Damora Therapeutics Inc. since August 2026. Dr. Cheng serves as Board Chairman at Expedition Therapeutics Inc since October 2025. Dr. Cheng is CEO, President & Chairman of the Board of Avere Therapeutics, Inc. He serves as Director of Vera Therapeutics, Inc. since May 2017. He served as Director of Arbutus Biopharma Corporation since August 17, 2019 until May 25, 2022. He served as Chief Medical Officer & Executive Vice President of Gilead Sciences, Inc., since March 2018 until September 7, 2018. He served as Independent Member of Supervisory Board at MorphoSys AG since May 18, 2022 until May 2024. Dr. Cheng served as the President and Chief Executive Officer at Akero Therapeutics Inc. since September 10, 2018 until December 9, 2025 and serves as its Director since 2018 until December 9, 2025. He served as an Executive Vice President of Clinical Research & Development Operations at Gilead Sciences Inc. since January 2015 until March 2018. Dr. Cheng served as an Executive Vice President of HIV Therapeutics and Development Operations at Gilead Sciences Inc. since January 28, 2015. Dr. Cheng served as Senior Vice President of HIV Therapeutics at Gilead Sciences, Inc. until January 28, 2015. He is responsible for leading the company’s Medical Affairs organization, as well as overseeing clinical development for the company’s programs in HIV/AIDS. Dr. Cheng served as Senior Vice President of Development Operations at Gilead Sciences Inc., since January 2009 until March 2018. During his tenure at Gilead, he also led the clinical development operations for several other therapeutic areas including oncology, inflammatory, respiratory and cardiovascular indications. Dr. Cheng is responsible for Gilead's biometrics, clinical operations, drug safety and public health, project and portfolio management and regulatory affairs activities. He joined Gilead in 1999 and served as Vice President, Clinical Research, overseeing clinical development activities for Gilead's development-stage programs in HIV/AIDS. He has been Director of Global Virus Network since January 2013. In August 2019, he joined Arbutus Biopharma Corporation. Dr. Cheng serves on the board of directors of MorphoSys AG (Nasdaq: MOR). From April 2018 to November 2018, Dr. Cheng served on the board of directors of Syntimmune, Inc., a biotechnology company, which was acquired by Alexion Pharmaceuticals Inc. Dr. Cheng completed his internal medicine residency at UCLA and was board certified in internal medicine. Dr. Cheng received his Medical Degree and PhD in Cellular and Molecular Biology from Columbia University College of Physicians and Surgeons and holds a B.A. in biology from the Johns Hopkins University.
Positions
- Company NameVera Therapeutics, Inc.Stock CodeVERAPositionIndependent DirectorColleagues
- MWMarshall W. FordyceFounder, President, CEO & Director
- MMMichael M. MorrisseyIndependent Chairman of the Board
- SPSean P. GrantChief Financial Officer
- DLDavid L. JohnsonChief Opearating Officer
- RMRobert M. BrennerChief Medical Officer
- JRJoseph R. YoungSenior VP of Finance & Chief Accounting Officer
- ACAndrew ChengIndependent Director
- SWScott William MorrisonIndependent Director
- PGPatrick Gerald EnrightIndependent Director
- Company NameTCGX Acquisition Corp.Stock CodeTCGXPositionIndependent Director
